PubMed Health⌕ Search

Biomedical subjects

Susan E Lenhart

Publications and source records attributed to Susan E Lenhart.

2 recordsLinked to original sources

Pharmacist involvement in a multidisciplinary inpatient medication education program.

The development of a multidisciplinary inpatient medication education program is described. A multidisciplinary group designed and implemented a medication education program with defined roles for both nurses and pharmacists. Nurses provided medication education to patients during each medication administration using specially designed assessment and teaching tools. The nursing staff submitted requests for pharmacist consultations for patients with complex medication regimens, who were admitted because of a drug-related problem or who required additional teaching as determined through the medication education assessment form. A complex medication regimen was defined as the administration of oral medication more than five different times per day, the start of at least 5 new medications that would be continued at discharge, or the prescribing of at least 10 medications to be taken daily that would be continued at discharge. Pharmacists provided education for 19% of admitted patients during a six-month period. As a result of pharmacists' interactions with prescribers and nurses, the number of medications was reduced in 12% of these patients, and the number of medication administrations each day was reduced in 19% of patients. In addition, for 33% of patients, pharmacists contacted the prescriber to make recommendations beyond the scope of the medication education program that optimized and simplified the patient's drug regimen. The development of a structured medication education program allowed patients to receive medication education throughout their hospitalization from both nurses and pharmacists. Pharmacists provided education for patients at highest risk for noncompliance or poor outcomes. Full implementation of a medication education program involving staff pharmacists is planned.

Administration, Oral↗

Tinzaparin sodium: a low-molecular-weight heparin.

The chemistry, pharmacokinetics, pharmacodynamics, clinical efficacy, dosage and administration, adverse effects, and therapeutic role of tinzaparin are reviewed. Tinzaparin is a low-molecular-weight heparin (LMWH) with antithrombotic properties. It has FDA-approved labeling for use in the treatment of acute symptomatic deep-vein thrombosis (DVT) with or without pulmonary embolism (PE) when administered in conjunction with warfarin sodium. Tinzaparin works by inhibiting reactions that lead to the clotting of blood. The much-improved pharmacokinetics of tinzaparin compared with unfractionated heparin (UFH) are due to its lower affinity for heparin-binding proteins and endothelial cells, shorter fractionated heparin chain (which allows for better bioavailability), and unsaturable renal elimination. Clinical trials have demonstrated that tinzaparin is at least as safe and effective as UFH for the treatment of DVT. Tinzaparin may also be effective for unlabeled uses, such as prophylaxis of venous thromboembolism (VTE) after orthopedic, general, and abdominal surgery, although more data are needed to define the optimal dose for this indication. The recommended dosage of tinzaparin for the treatment of established DVT with or without PE is 175 anti-factor Xa IU per kilogram of body weight administered subcutaneously once daily for at least six days until the patient achieves adequate anticoagulation with warfarin. As with other LMWHs, the most common complication of tinzaparin therapy is bleeding. Tinzaparin offers an additional treatment option for VTE.

Biological Availability↗